{"transactions":[{"id":721270,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":34002,"kind":"person","name":"Barton Shane","position":1,"cik":"0001836297","reported_name":"Barton Shane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-01T20:27:06.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":false,"shares":7861,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":67941,"derivative":{"exercise_price":4.38,"expiration_date":"2035-02-17","underlying":"Common Stock","underlying_shares":7861},"source":{"system":"sec-edgar","filing":"0001836297-26-000005","document":"form4-07012026_080701.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000183629726000005/form4-07012026_080701.xml","form_type":"4"}},{"id":721269,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":34002,"kind":"person","name":"Barton Shane","position":1,"cik":"0001836297","reported_name":"Barton Shane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-01T20:27:06.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":false,"shares":4065,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option vested as to 1/4th of the total award on October 26, 2024, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":26977,"derivative":{"exercise_price":4.3,"expiration_date":"2034-12-17","underlying":"Common Stock","underlying_shares":4065},"source":{"system":"sec-edgar","filing":"0001836297-26-000005","document":"form4-07012026_080701.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000183629726000005/form4-07012026_080701.xml","form_type":"4"}},{"id":721268,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":34002,"kind":"person","name":"Barton Shane","position":1,"cik":"0001836297","reported_name":"Barton Shane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-01T20:27:06.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":false,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vested as to 1/4th of the total award on October 17, 2024, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":17016,"derivative":{"exercise_price":8.39,"expiration_date":"2034-04-16","underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001836297-26-000005","document":"form4-07012026_080701.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000183629726000005/form4-07012026_080701.xml","form_type":"4"}},{"id":721267,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":34002,"kind":"person","name":"Barton Shane","position":1,"cik":"0001836297","reported_name":"Barton Shane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-01T20:27:06.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":false,"shares":4290,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vested as to 1/4th of the total award on September 25, 2024, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":13299,"derivative":{"exercise_price":10.85,"expiration_date":"2033-09-26","underlying":"Common Stock","underlying_shares":4290},"source":{"system":"sec-edgar","filing":"0001836297-26-000005","document":"form4-07012026_080701.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000183629726000005/form4-07012026_080701.xml","form_type":"4"}},{"id":721266,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":34002,"kind":"person","name":"Barton Shane","position":1,"cik":"0001836297","reported_name":"Barton Shane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-01T20:27:06.000Z","date":"2026-06-29","kind":"exercise","planned":true,"acquired":false,"shares":14198,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":75802,"derivative":{"exercise_price":4.38,"expiration_date":"2035-02-17","underlying":"Common Stock","underlying_shares":14198},"source":{"system":"sec-edgar","filing":"0001836297-26-000005","document":"form4-07012026_080701.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000183629726000005/form4-07012026_080701.xml","form_type":"4"}},{"id":721265,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":34002,"kind":"person","name":"Barton Shane","position":1,"cik":"0001836297","reported_name":"Barton Shane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-01T20:27:06.000Z","date":"2026-06-29","kind":"exercise","planned":true,"acquired":false,"shares":8958,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option vested as to 1/4th of the total award on October 26, 2024, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":31042,"derivative":{"exercise_price":4.3,"expiration_date":"2034-12-17","underlying":"Common Stock","underlying_shares":8958},"source":{"system":"sec-edgar","filing":"0001836297-26-000005","document":"form4-07012026_080701.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000183629726000005/form4-07012026_080701.xml","form_type":"4"}},{"id":721264,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":34002,"kind":"person","name":"Barton Shane","position":1,"cik":"0001836297","reported_name":"Barton Shane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-01T20:27:06.000Z","date":"2026-06-29","kind":"exercise","planned":true,"acquired":false,"shares":7261,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vested as to 1/4th of the total award on October 17, 2024, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":21016,"derivative":{"exercise_price":8.39,"expiration_date":"2034-04-16","underlying":"Common Stock","underlying_shares":7261},"source":{"system":"sec-edgar","filing":"0001836297-26-000005","document":"form4-07012026_080701.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000183629726000005/form4-07012026_080701.xml","form_type":"4"}},{"id":721263,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":34002,"kind":"person","name":"Barton Shane","position":1,"cik":"0001836297","reported_name":"Barton Shane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-01T20:27:06.000Z","date":"2026-06-29","kind":"exercise","planned":true,"acquired":false,"shares":9301,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vested as to 1/4th of the total award on September 25, 2024, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":17589,"derivative":{"exercise_price":10.85,"expiration_date":"2033-09-26","underlying":"Common Stock","underlying_shares":9301},"source":{"system":"sec-edgar","filing":"0001836297-26-000005","document":"form4-07012026_080701.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000183629726000005/form4-07012026_080701.xml","form_type":"4"}},{"id":721262,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":34002,"kind":"person","name":"Barton Shane","position":1,"cik":"0001836297","reported_name":"Barton Shane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common Stock","published_at":"2026-07-01T20:27:06.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":20216,"price":25.1868,"value":509176.3488,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.42 per share, inclusive."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001836297-26-000005","document":"form4-07012026_080701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000183629726000005/form4-07012026_080701.xml","form_type":"4"}},{"id":721261,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":34002,"kind":"person","name":"Barton Shane","position":1,"cik":"0001836297","reported_name":"Barton Shane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common Stock","published_at":"2026-07-01T20:27:06.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":true,"shares":7861,"price":4.38,"value":34431.18,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025."}],"balance_after":20216,"source":{"system":"sec-edgar","filing":"0001836297-26-000005","document":"form4-07012026_080701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000183629726000005/form4-07012026_080701.xml","form_type":"4"}},{"id":721260,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":34002,"kind":"person","name":"Barton Shane","position":1,"cik":"0001836297","reported_name":"Barton Shane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common Stock","published_at":"2026-07-01T20:27:06.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":true,"shares":4065,"price":4.3,"value":17479.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025."}],"balance_after":12355,"source":{"system":"sec-edgar","filing":"0001836297-26-000005","document":"form4-07012026_080701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000183629726000005/form4-07012026_080701.xml","form_type":"4"}},{"id":721259,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":34002,"kind":"person","name":"Barton Shane","position":1,"cik":"0001836297","reported_name":"Barton Shane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common Stock","published_at":"2026-07-01T20:27:06.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":true,"shares":4000,"price":8.39,"value":33560.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025."}],"balance_after":8290,"source":{"system":"sec-edgar","filing":"0001836297-26-000005","document":"form4-07012026_080701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000183629726000005/form4-07012026_080701.xml","form_type":"4"}},{"id":721258,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":34002,"kind":"person","name":"Barton Shane","position":1,"cik":"0001836297","reported_name":"Barton Shane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common Stock","published_at":"2026-07-01T20:27:06.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":true,"shares":4290,"price":10.85,"value":46546.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025."}],"balance_after":4290,"source":{"system":"sec-edgar","filing":"0001836297-26-000005","document":"form4-07012026_080701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000183629726000005/form4-07012026_080701.xml","form_type":"4"}},{"id":721257,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":34002,"kind":"person","name":"Barton Shane","position":1,"cik":"0001836297","reported_name":"Barton Shane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common Stock","published_at":"2026-07-01T20:27:06.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":42350,"price":25.2084,"value":1067575.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.79 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001836297-26-000005","document":"form4-07012026_080701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000183629726000005/form4-07012026_080701.xml","form_type":"4"}},{"id":721256,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":34002,"kind":"person","name":"Barton Shane","position":1,"cik":"0001836297","reported_name":"Barton Shane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common Stock","published_at":"2026-07-01T20:27:06.000Z","date":"2026-06-29","kind":"exercise","planned":true,"acquired":true,"shares":14198,"price":4.38,"value":62187.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025."}],"balance_after":42350,"source":{"system":"sec-edgar","filing":"0001836297-26-000005","document":"form4-07012026_080701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000183629726000005/form4-07012026_080701.xml","form_type":"4"}},{"id":721255,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":34002,"kind":"person","name":"Barton Shane","position":1,"cik":"0001836297","reported_name":"Barton Shane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common Stock","published_at":"2026-07-01T20:27:06.000Z","date":"2026-06-29","kind":"exercise","planned":true,"acquired":true,"shares":8958,"price":4.3,"value":38519.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025."}],"balance_after":28152,"source":{"system":"sec-edgar","filing":"0001836297-26-000005","document":"form4-07012026_080701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000183629726000005/form4-07012026_080701.xml","form_type":"4"}},{"id":721254,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":34002,"kind":"person","name":"Barton Shane","position":1,"cik":"0001836297","reported_name":"Barton Shane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common Stock","published_at":"2026-07-01T20:27:06.000Z","date":"2026-06-29","kind":"exercise","planned":true,"acquired":true,"shares":7261,"price":8.39,"value":60919.79,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025."}],"balance_after":19194,"source":{"system":"sec-edgar","filing":"0001836297-26-000005","document":"form4-07012026_080701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000183629726000005/form4-07012026_080701.xml","form_type":"4"}},{"id":721253,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":34002,"kind":"person","name":"Barton Shane","position":1,"cik":"0001836297","reported_name":"Barton Shane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common Stock","published_at":"2026-07-01T20:27:06.000Z","date":"2026-06-29","kind":"exercise","planned":true,"acquired":true,"shares":9301,"price":10.85,"value":100915.85,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025."}],"balance_after":11933,"source":{"system":"sec-edgar","filing":"0001836297-26-000005","document":"form4-07012026_080701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000183629726000005/form4-07012026_080701.xml","form_type":"4"}},{"id":739880,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":38749,"kind":"person","name":"Pande Vijay Satyanand","position":1,"cik":"0001840663","reported_name":"Pande Vijay Satyanand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T20:37:11.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The entire option award shall vest on the earlier of:  (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date."}],"balance_after":22000,"derivative":{"exercise_price":15.48,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001840663-26-000002","document":"form4-06122026_080608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000184066326000002/form4-06122026_080608.xml","form_type":"4"}},{"id":739879,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":36308,"kind":"person","name":"Hemrajani Rekha","position":1,"cik":"0001771213","reported_name":"Hemrajani Rekha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T20:35:46.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The entire option award shall vest on the earlier of:  (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date."}],"balance_after":22000,"derivative":{"exercise_price":15.48,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001771213-26-000004","document":"form4-06122026_080642.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000177121326000004/form4-06122026_080642.xml","form_type":"4"}},{"id":739878,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T20:34:10.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The entire option award shall vest on the earlier of:  (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date."}],"balance_after":22000,"derivative":{"exercise_price":15.48,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001245624-26-000002","document":"form4-06122026_080606.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000124562426000002/form4-06122026_080606.xml","form_type":"4"}},{"id":739877,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":847,"kind":"person","name":"ENRIGHT PATRICK G","position":1,"cik":"0001253886","reported_name":"ENRIGHT PATRICK G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T20:33:04.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The entire option award shall vest on the earlier of:  (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date."}],"balance_after":22000,"derivative":{"exercise_price":15.48,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001253886-26-000006","document":"form4-06122026_080600.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000125388626000006/form4-06122026_080600.xml","form_type":"4"}},{"id":739876,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T20:31:53.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The entire option award shall vest on the earlier of:  (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date."}],"balance_after":22000,"derivative":{"exercise_price":15.48,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001573785-26-000003","document":"form4-06122026_080647.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000157378526000003/form4-06122026_080647.xml","form_type":"4"}},{"id":739875,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":11993,"kind":"person","name":"GARNIER JEAN PIERRE","position":1,"cik":"0001184175","reported_name":"GARNIER JEAN PIERRE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T20:29:18.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The entire option award shall vest on the earlier of:  (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date."}],"balance_after":22000,"derivative":{"exercise_price":15.48,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001184175-26-000002","document":"form4-06122026_080614.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000118417526000002/form4-06122026_080614.xml","form_type":"4"}},{"id":801273,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-24T20:19:14.000Z","date":"2026-04-23","kind":"exercise","planned":false,"acquired":false,"shares":3542,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":155833,"derivative":{"exercise_price":4.38,"expiration_date":"2035-02-17","underlying":"Common Stock","underlying_shares":3542},"source":{"system":"sec-edgar","filing":"0001120478-26-000013","document":"form4-04242026_080410.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000112047826000013/form4-04242026_080410.xml","form_type":"4"}},{"id":801272,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-04-24T20:19:14.000Z","date":"2026-04-23","kind":"exercise","planned":false,"acquired":true,"shares":3542,"price":4.38,"value":15513.96,"ownership":{"direct":true},"balance_after":36575,"source":{"system":"sec-edgar","filing":"0001120478-26-000013","document":"form4-04242026_080410.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000112047826000013/form4-04242026_080410.xml","form_type":"4"}},{"id":816476,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":53847,"kind":"person","name":"RUBIN PAUL D","position":1,"cik":"0001210905","reported_name":"RUBIN PAUL D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-03T20:07:11.000Z","date":"2026-04-01","kind":"exercise","planned":true,"acquired":false,"shares":3383,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on April 1, 2022, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"exercise_price":6.57,"expiration_date":"2032-05-28","underlying":"Common Stock","underlying_shares":3383},"source":{"system":"sec-edgar","filing":"0001210905-26-000011","document":"form4-04032026_080407.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000121090526000011/form4-04032026_080407.xml","form_type":"4"}},{"id":816475,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":53847,"kind":"person","name":"RUBIN PAUL D","position":1,"cik":"0001210905","reported_name":"RUBIN PAUL D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-03T20:07:11.000Z","date":"2026-04-01","kind":"exercise","planned":true,"acquired":false,"shares":5437,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option is fully vested.  Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on May 11, 2024."}],"balance_after":0,"derivative":{"exercise_price":4.11,"expiration_date":"2030-06-30","underlying":"Common Stock","underlying_shares":5437},"source":{"system":"sec-edgar","filing":"0001210905-26-000011","document":"form4-04032026_080407.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000121090526000011/form4-04032026_080407.xml","form_type":"4"}},{"id":816474,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":53847,"kind":"person","name":"RUBIN PAUL D","position":1,"cik":"0001210905","reported_name":"RUBIN PAUL D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-04-03T20:07:11.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":8820,"price":17.81,"value":157084.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001210905-26-000011","document":"form4-04032026_080407.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000121090526000011/form4-04032026_080407.xml","form_type":"4"}},{"id":816473,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":53847,"kind":"person","name":"RUBIN PAUL D","position":1,"cik":"0001210905","reported_name":"RUBIN PAUL D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-04-03T20:07:11.000Z","date":"2026-04-01","kind":"exercise","planned":true,"acquired":true,"shares":3383,"price":6.57,"value":22226.31,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024."}],"balance_after":8820,"source":{"system":"sec-edgar","filing":"0001210905-26-000011","document":"form4-04032026_080407.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000121090526000011/form4-04032026_080407.xml","form_type":"4"}},{"id":816472,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":53847,"kind":"person","name":"RUBIN PAUL D","position":1,"cik":"0001210905","reported_name":"RUBIN PAUL D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-04-03T20:07:11.000Z","date":"2026-04-01","kind":"exercise","planned":true,"acquired":true,"shares":5437,"price":4.11,"value":22346.07,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024."}],"balance_after":5437,"source":{"system":"sec-edgar","filing":"0001210905-26-000011","document":"form4-04032026_080407.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000121090526000011/form4-04032026_080407.xml","form_type":"4"}},{"id":867429,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":53847,"kind":"person","name":"RUBIN PAUL D","position":1,"cik":"0001210905","reported_name":"RUBIN PAUL D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-03T21:46:45.000Z","date":"2026-03-02","kind":"exercise","planned":true,"acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on April 1, 2022, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":3383,"derivative":{"exercise_price":6.57,"expiration_date":"2032-05-28","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001210905-26-000009","document":"form4-03032026_090341.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000121090526000009/form4-03032026_090341.xml","form_type":"4"}},{"id":867428,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":53847,"kind":"person","name":"RUBIN PAUL D","position":1,"cik":"0001210905","reported_name":"RUBIN PAUL D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-03T21:46:45.000Z","date":"2026-03-02","kind":"exercise","planned":true,"acquired":false,"shares":5433,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option is fully vested.  Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on May 11, 2024."}],"balance_after":5437,"derivative":{"exercise_price":4.11,"expiration_date":"2030-06-30","underlying":"Common Stock","underlying_shares":5433},"source":{"system":"sec-edgar","filing":"0001210905-26-000009","document":"form4-03032026_090341.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000121090526000009/form4-03032026_090341.xml","form_type":"4"}},{"id":867427,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":53847,"kind":"person","name":"RUBIN PAUL D","position":1,"cik":"0001210905","reported_name":"RUBIN PAUL D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-03-03T21:46:45.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":7433,"price":20.3,"value":150889.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001210905-26-000009","document":"form4-03032026_090341.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000121090526000009/form4-03032026_090341.xml","form_type":"4"}},{"id":867426,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":53847,"kind":"person","name":"RUBIN PAUL D","position":1,"cik":"0001210905","reported_name":"RUBIN PAUL D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-03-03T21:46:45.000Z","date":"2026-03-02","kind":"exercise","planned":true,"acquired":true,"shares":2000,"price":6.57,"value":13140.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024."}],"balance_after":7433,"source":{"system":"sec-edgar","filing":"0001210905-26-000009","document":"form4-03032026_090341.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000121090526000009/form4-03032026_090341.xml","form_type":"4"}},{"id":867425,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":53847,"kind":"person","name":"RUBIN PAUL D","position":1,"cik":"0001210905","reported_name":"RUBIN PAUL D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-03-03T21:46:45.000Z","date":"2026-03-02","kind":"exercise","planned":true,"acquired":true,"shares":5433,"price":4.11,"value":22329.63,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024."}],"balance_after":5433,"source":{"system":"sec-edgar","filing":"0001210905-26-000009","document":"form4-03032026_090341.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000121090526000009/form4-03032026_090341.xml","form_type":"4"}},{"id":870291,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-03T21:44:53.000Z","date":"2026-03-01","kind":"exercise","planned":false,"acquired":false,"shares":3542,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":159375,"derivative":{"exercise_price":4.38,"expiration_date":"2035-02-17","underlying":"Common Stock","underlying_shares":3542},"source":{"system":"sec-edgar","filing":"0001120478-26-000011","document":"form4-03032026_090347.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000112047826000011/form4-03032026_090347.xml","form_type":"4"}},{"id":870290,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-03T21:44:53.000Z","date":"2026-03-01","kind":"exercise","planned":false,"acquired":true,"shares":3542,"price":4.38,"value":15513.96,"ownership":{"direct":true},"balance_after":33033,"source":{"system":"sec-edgar","filing":"0001120478-26-000011","document":"form4-03032026_090347.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000112047826000011/form4-03032026_090347.xml","form_type":"4"}},{"id":893415,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":53847,"kind":"person","name":"RUBIN PAUL D","position":1,"cik":"0001210905","reported_name":"RUBIN PAUL D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-19T21:42:42.000Z","date":"2026-02-17","kind":"grant","planned":false,"acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":110000,"derivative":{"exercise_price":19.63,"expiration_date":"2036-02-16","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001210905-26-000007","document":"form4-02192026_090237.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000121090526000007/form4-02192026_090237.xml","form_type":"4"}},{"id":893412,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":65667,"kind":"person","name":"Morgen Eric","position":1,"cik":"0002036289","reported_name":"Morgen Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-19T21:40:40.000Z","date":"2026-02-17","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the holder's continued service to the Issuer on each vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents an employee stock option directly held by the reporting person's spouse."}],"balance_after":12500,"derivative":{"exercise_price":19.63,"expiration_date":"2036-02-16","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0002036289-26-000002","document":"form4-02192026_090237.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000203628926000002/form4-02192026_090237.xml","form_type":"4"}},{"id":893411,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":65667,"kind":"person","name":"Morgen Eric","position":1,"cik":"0002036289","reported_name":"Morgen Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-19T21:40:40.000Z","date":"2026-02-17","kind":"grant","planned":false,"acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":110000,"derivative":{"exercise_price":19.63,"expiration_date":"2036-02-16","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0002036289-26-000002","document":"form4-02192026_090237.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000203628926000002/form4-02192026_090237.xml","form_type":"4"}},{"id":894407,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-19T21:38:22.000Z","date":"2026-02-17","kind":"grant","planned":false,"acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":110000,"derivative":{"exercise_price":19.63,"expiration_date":"2036-02-16","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001120478-26-000009","document":"form4-02192026_090219.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000112047826000009/form4-02192026_090219.xml","form_type":"4"}},{"id":893414,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":34002,"kind":"person","name":"Barton Shane","position":1,"cik":"0001836297","reported_name":"Barton Shane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-19T21:34:46.000Z","date":"2026-02-17","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":45000,"derivative":{"exercise_price":19.63,"expiration_date":"2036-02-16","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001836297-26-000002","document":"form4-02192026_090243.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000183629726000002/form4-02192026_090243.xml","form_type":"4"}},{"id":893796,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":65690,"kind":"person","name":"Fortney Kristen","position":1,"cik":"0002032751","reported_name":"Fortney Kristen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-19T16:36:41.000Z","date":"2026-02-17","kind":"grant","planned":false,"acquired":true,"shares":330000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":330000,"derivative":{"exercise_price":19.63,"expiration_date":"2036-02-16","underlying":"Common Stock","underlying_shares":330000},"source":{"system":"sec-edgar","filing":"0002032751-26-000010","document":"form4-02192026_090238.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2032751/000203275126000010/form4-02192026_090238.xml","form_type":"4"}},{"id":921946,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":53847,"kind":"person","name":"RUBIN PAUL D","position":1,"cik":"0001210905","reported_name":"RUBIN PAUL D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-03T21:26:11.000Z","date":"2026-02-02","kind":"exercise","planned":true,"acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on April 1, 2022, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":5383,"derivative":{"exercise_price":6.57,"expiration_date":"2032-05-28","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001210905-26-000005","document":"form4-02032026_090207.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000121090526000005/form4-02032026_090207.xml","form_type":"4"}},{"id":921945,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":53847,"kind":"person","name":"RUBIN PAUL D","position":1,"cik":"0001210905","reported_name":"RUBIN PAUL D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-03T21:26:11.000Z","date":"2026-02-02","kind":"exercise","planned":true,"acquired":false,"shares":5433,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option is fully vested.  Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on May 11, 2024."}],"balance_after":10870,"derivative":{"exercise_price":4.11,"expiration_date":"2030-06-30","underlying":"Common Stock","underlying_shares":5433},"source":{"system":"sec-edgar","filing":"0001210905-26-000005","document":"form4-02032026_090207.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000121090526000005/form4-02032026_090207.xml","form_type":"4"}},{"id":921944,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":53847,"kind":"person","name":"RUBIN PAUL D","position":1,"cik":"0001210905","reported_name":"RUBIN PAUL D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-02-03T21:26:11.000Z","date":"2026-02-02","kind":"sale","planned":true,"acquired":false,"shares":7433,"price":18.75,"value":139368.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001210905-26-000005","document":"form4-02032026_090207.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000121090526000005/form4-02032026_090207.xml","form_type":"4"}},{"id":921943,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":53847,"kind":"person","name":"RUBIN PAUL D","position":1,"cik":"0001210905","reported_name":"RUBIN PAUL D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-02-03T21:26:11.000Z","date":"2026-02-02","kind":"exercise","planned":true,"acquired":true,"shares":2000,"price":6.57,"value":13140.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024."}],"balance_after":7433,"source":{"system":"sec-edgar","filing":"0001210905-26-000005","document":"form4-02032026_090207.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000121090526000005/form4-02032026_090207.xml","form_type":"4"}},{"id":921942,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":53847,"kind":"person","name":"RUBIN PAUL D","position":1,"cik":"0001210905","reported_name":"RUBIN PAUL D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-02-03T21:26:11.000Z","date":"2026-02-02","kind":"exercise","planned":true,"acquired":true,"shares":5433,"price":4.11,"value":22329.63,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024."}],"balance_after":5433,"source":{"system":"sec-edgar","filing":"0001210905-26-000005","document":"form4-02032026_090207.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000121090526000005/form4-02032026_090207.xml","form_type":"4"}},{"id":922831,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-03T21:23:00.000Z","date":"2026-02-01","kind":"exercise","planned":false,"acquired":false,"shares":3541,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":162917,"derivative":{"exercise_price":4.38,"expiration_date":"2035-02-17","underlying":"Common Stock","underlying_shares":3541},"source":{"system":"sec-edgar","filing":"0001120478-26-000007","document":"form4-02032026_090256.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000112047826000007/form4-02032026_090256.xml","form_type":"4"}},{"id":922830,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-03T21:23:00.000Z","date":"2026-02-01","kind":"exercise","planned":false,"acquired":true,"shares":3541,"price":4.38,"value":15509.58,"ownership":{"direct":true},"balance_after":29491,"source":{"system":"sec-edgar","filing":"0001120478-26-000007","document":"form4-02032026_090256.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000112047826000007/form4-02032026_090256.xml","form_type":"4"}},{"id":934599,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-21T21:20:56.000Z","date":"2026-01-16","kind":"exercise","planned":false,"acquired":false,"shares":3542,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":166458,"derivative":{"exercise_price":4.38,"expiration_date":"2035-02-17","underlying":"Common Stock","underlying_shares":3542},"source":{"system":"sec-edgar","filing":"0001120478-26-000005","document":"form4-01212026_090153.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000112047826000005/form4-01212026_090153.xml","form_type":"4"}},{"id":934598,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-21T21:20:56.000Z","date":"2026-01-16","kind":"exercise","planned":false,"acquired":true,"shares":3542,"price":4.38,"value":15513.96,"ownership":{"direct":true},"balance_after":25950,"source":{"system":"sec-edgar","filing":"0001120478-26-000005","document":"form4-01212026_090153.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000112047826000005/form4-01212026_090153.xml","form_type":"4"}},{"id":938714,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-15T21:22:20.000Z","date":"2026-01-13","kind":"exercise","planned":true,"acquired":false,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on May 17, 2024, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.  Additionally, the entire award is exercisable at any time pursuant to an early exercise feature of the option award."}],"balance_after":92587,"derivative":{"exercise_price":8.39,"expiration_date":"2034-04-16","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001120478-26-000003","document":"form4-01152026_090117.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000112047826000003/form4-01152026_090117.xml","form_type":"4"}},{"id":938713,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-15T21:22:20.000Z","date":"2026-01-13","kind":"sale","planned":true,"acquired":false,"shares":1923,"price":21.0808,"value":40538.3784,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.04 to $21.15 per share, inclusive."}],"balance_after":22408,"source":{"system":"sec-edgar","filing":"0001120478-26-000003","document":"form4-01152026_090117.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000112047826000003/form4-01152026_090117.xml","form_type":"4"}},{"id":938712,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-15T21:22:20.000Z","date":"2026-01-13","kind":"sale","planned":true,"acquired":false,"shares":11663,"price":20.5392,"value":239548.6896,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.04 to $21.02 per share, inclusive."}],"balance_after":24331,"source":{"system":"sec-edgar","filing":"0001120478-26-000003","document":"form4-01152026_090117.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000112047826000003/form4-01152026_090117.xml","form_type":"4"}},{"id":938711,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-15T21:22:20.000Z","date":"2026-01-13","kind":"sale","planned":true,"acquired":false,"shares":4440,"price":19.4526,"value":86369.544,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.00 to $19.86 per share, inclusive."}],"balance_after":35994,"source":{"system":"sec-edgar","filing":"0001120478-26-000003","document":"form4-01152026_090117.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000112047826000003/form4-01152026_090117.xml","form_type":"4"}},{"id":938710,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-15T21:22:20.000Z","date":"2026-01-13","kind":"sale","planned":true,"acquired":false,"shares":8974,"price":18.4278,"value":165371.0772,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.91 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 5 of this Form 4."}],"balance_after":40434,"source":{"system":"sec-edgar","filing":"0001120478-26-000003","document":"form4-01152026_090117.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000112047826000003/form4-01152026_090117.xml","form_type":"4"}},{"id":938709,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-15T21:22:20.000Z","date":"2026-01-13","kind":"exercise","planned":true,"acquired":true,"shares":27000,"price":8.39,"value":226530.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2024."}],"balance_after":49408,"source":{"system":"sec-edgar","filing":"0001120478-26-000003","document":"form4-01152026_090117.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000112047826000003/form4-01152026_090117.xml","form_type":"4"}},{"id":938611,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":65690,"kind":"person","name":"Fortney Kristen","position":1,"cik":"0002032751","reported_name":"Fortney Kristen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-15T16:20:14.000Z","date":"2026-01-13","kind":"sale","planned":true,"acquired":false,"shares":233107,"price":18.1163,"value":4223036.3441,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.385 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":976949,"source":{"system":"sec-edgar","filing":"0002032751-26-000003","document":"form4-01152026_090111.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2032751/000203275126000003/form4-01152026_090111.xml","form_type":"4"}},{"id":946823,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":53847,"kind":"person","name":"RUBIN PAUL D","position":1,"cik":"0001210905","reported_name":"RUBIN PAUL D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-06T21:24:01.000Z","date":"2026-01-02","kind":"exercise","planned":true,"acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on April 1, 2022, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":7383,"derivative":{"exercise_price":6.57,"expiration_date":"2032-05-28","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001210905-26-000002","document":"form4-01062026_090157.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000121090526000002/form4-01062026_090157.xml","form_type":"4"}},{"id":946822,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":53847,"kind":"person","name":"RUBIN PAUL D","position":1,"cik":"0001210905","reported_name":"RUBIN PAUL D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-06T21:24:01.000Z","date":"2026-01-02","kind":"exercise","planned":true,"acquired":false,"shares":5433,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully vested.  Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on May 11, 2024."}],"balance_after":16303,"derivative":{"exercise_price":4.11,"expiration_date":"2030-06-30","underlying":"Common Stock","underlying_shares":5433},"source":{"system":"sec-edgar","filing":"0001210905-26-000002","document":"form4-01062026_090157.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000121090526000002/form4-01062026_090157.xml","form_type":"4"}},{"id":946821,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":53847,"kind":"person","name":"RUBIN PAUL D","position":1,"cik":"0001210905","reported_name":"RUBIN PAUL D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-06T21:24:01.000Z","date":"2026-01-02","kind":"sale","planned":true,"acquired":false,"shares":7433,"price":12.8468,"value":95490.2644,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.571 to $13.242 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001210905-26-000002","document":"form4-01062026_090157.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000121090526000002/form4-01062026_090157.xml","form_type":"4"}},{"id":946820,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":53847,"kind":"person","name":"RUBIN PAUL D","position":1,"cik":"0001210905","reported_name":"RUBIN PAUL D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-06T21:24:01.000Z","date":"2026-01-02","kind":"exercise","planned":true,"acquired":true,"shares":2000,"price":6.57,"value":13140.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024."}],"balance_after":7433,"source":{"system":"sec-edgar","filing":"0001210905-26-000002","document":"form4-01062026_090157.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000121090526000002/form4-01062026_090157.xml","form_type":"4"}},{"id":946819,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":53847,"kind":"person","name":"RUBIN PAUL D","position":1,"cik":"0001210905","reported_name":"RUBIN PAUL D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-06T21:24:01.000Z","date":"2026-01-02","kind":"exercise","planned":true,"acquired":true,"shares":5433,"price":4.11,"value":22329.63,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024."}],"balance_after":5433,"source":{"system":"sec-edgar","filing":"0001210905-26-000002","document":"form4-01062026_090157.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000121090526000002/form4-01062026_090157.xml","form_type":"4"}},{"id":972681,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":53847,"kind":"person","name":"RUBIN PAUL D","position":1,"cik":"0001210905","reported_name":"RUBIN PAUL D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-11T21:21:15.000Z","date":"2025-12-09","kind":"exercise","planned":true,"acquired":false,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on April 1, 2022, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":9383,"derivative":{"exercise_price":6.57,"expiration_date":"2032-05-28","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001210905-25-000006","document":"form4-12112025_091211.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000121090525000006/form4-12112025_091211.xml","form_type":"4"}},{"id":972680,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":53847,"kind":"person","name":"RUBIN PAUL D","position":1,"cik":"0001210905","reported_name":"RUBIN PAUL D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-12-11T21:21:15.000Z","date":"2025-12-09","kind":"sale","planned":true,"acquired":false,"shares":18000,"price":12,"value":216000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001210905-25-000006","document":"form4-12112025_091211.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000121090525000006/form4-12112025_091211.xml","form_type":"4"}},{"id":972679,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":53847,"kind":"person","name":"RUBIN PAUL D","position":1,"cik":"0001210905","reported_name":"RUBIN PAUL D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-12-11T21:21:15.000Z","date":"2025-12-09","kind":"exercise","planned":true,"acquired":true,"shares":18000,"price":6.57,"value":118260.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024."}],"balance_after":18000,"source":{"system":"sec-edgar","filing":"0001210905-25-000006","document":"form4-12112025_091211.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000121090525000006/form4-12112025_091211.xml","form_type":"4"}},{"id":979057,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":53847,"kind":"person","name":"RUBIN PAUL D","position":1,"cik":"0001210905","reported_name":"RUBIN PAUL D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-05T23:20:44.000Z","date":"2025-12-04","kind":"exercise","planned":true,"acquired":false,"shares":68897,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully vested.  Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on May 11, 2024."}],"balance_after":21736,"derivative":{"exercise_price":4.11,"expiration_date":"2030-06-30","underlying":"Common Stock","underlying_shares":68897},"source":{"system":"sec-edgar","filing":"0001210905-25-000004","document":"form4-12052025_111241.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000121090525000004/form4-12052025_111241.xml","form_type":"4"}},{"id":979056,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":53847,"kind":"person","name":"RUBIN PAUL D","position":1,"cik":"0001210905","reported_name":"RUBIN PAUL D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-12-05T23:20:44.000Z","date":"2025-12-04","kind":"sale","planned":true,"acquired":false,"shares":68897,"price":10.1878,"value":701908.8566,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.96 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote"}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001210905-25-000004","document":"form4-12052025_111241.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000121090525000004/form4-12052025_111241.xml","form_type":"4"}},{"id":979055,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":53847,"kind":"person","name":"RUBIN PAUL D","position":1,"cik":"0001210905","reported_name":"RUBIN PAUL D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-12-05T23:20:44.000Z","date":"2025-12-04","kind":"exercise","planned":true,"acquired":true,"shares":68897,"price":4.11,"value":283166.67,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024."}],"balance_after":68897,"source":{"system":"sec-edgar","filing":"0001210905-25-000004","document":"form4-12052025_111241.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000121090525000004/form4-12052025_111241.xml","form_type":"4"}},{"id":1070278,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":38749,"kind":"person","name":"Pande Vijay Satyanand","position":1,"cik":"0001840663","reported_name":"Pande Vijay Satyanand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-11T20:14:24.000Z","date":"2025-08-07","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The entire option award shall vest on the earlier of:  (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date."}],"balance_after":22000,"derivative":{"exercise_price":4.32,"expiration_date":"2035-08-06","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001415889-25-021423","document":"form4-08112025_080820.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000141588925021423/form4-08112025_080820.xml","form_type":"4"}},{"id":1117969,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":36308,"kind":"person","name":"Hemrajani Rekha","position":1,"cik":"0001771213","reported_name":"Hemrajani Rekha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-09T20:47:25.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The entire option award shall vest on the earlier of:  (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date."}],"balance_after":22000,"derivative":{"exercise_price":4.44,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001415889-25-016296","document":"form4-06092025_080617.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000141588925016296/form4-06092025_080617.xml","form_type":"4"}},{"id":1117966,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-09T20:46:16.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The entire option award shall vest on the earlier of:  (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date."}],"balance_after":22000,"derivative":{"exercise_price":4.44,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001415889-25-016293","document":"form4-06092025_080608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000141588925016293/form4-06092025_080608.xml","form_type":"4"}},{"id":1117965,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":847,"kind":"person","name":"ENRIGHT PATRICK G","position":1,"cik":"0001253886","reported_name":"ENRIGHT PATRICK G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-09T20:44:06.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The entire option award shall vest on the earlier of:  (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date."}],"balance_after":22000,"derivative":{"exercise_price":4.44,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001415889-25-016286","document":"form4-06092025_080600.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000141588925016286/form4-06092025_080600.xml","form_type":"4"}},{"id":1117964,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-09T20:42:59.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The entire option award shall vest on the earlier of:  (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date."}],"balance_after":22000,"derivative":{"exercise_price":4.44,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001415889-25-016283","document":"form4-06092025_080644.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000141588925016283/form4-06092025_080644.xml","form_type":"4"}},{"id":1117963,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":11993,"kind":"person","name":"GARNIER JEAN PIERRE","position":1,"cik":"0001184175","reported_name":"GARNIER JEAN PIERRE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-09T20:41:04.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The entire option award shall vest on the earlier of:  (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date."}],"balance_after":22000,"derivative":{"exercise_price":4.44,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001415889-25-016281","document":"form4-06092025_080653.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000141588925016281/form4-06092025_080653.xml","form_type":"4"}},{"id":1215112,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":36308,"kind":"person","name":"Hemrajani Rekha","position":1,"cik":"0001771213","reported_name":"Hemrajani Rekha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-10T20:11:28.000Z","date":"2024-09-27","kind":"purchase","planned":false,"acquired":true,"shares":3000,"price":18,"value":54000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities were purchased through a directed share program in connection with the Issuer's initial public offering."}],"balance_after":3000,"source":{"system":"sec-edgar","filing":"0001415889-25-007506","document":"form4a-03102025_080325.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000141588925007506/form4a-03102025_080325.xml","form_type":"4/A","original_submission_date":"2024-09-27"}},{"id":1215111,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":34002,"kind":"person","name":"Barton Shane","position":1,"cik":"0001836297","reported_name":"Barton Shane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common Stock","published_at":"2025-03-10T20:10:37.000Z","date":"2024-09-27","kind":"purchase","planned":false,"acquired":true,"shares":2632,"price":18,"value":47376.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities were purchased through a directed share program in connection with the Issuer's initial public offering."}],"balance_after":2632,"source":{"system":"sec-edgar","filing":"0001415889-25-007505","document":"form4-03102025_080333.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000141588925007505/form4-03102025_080333.xml","form_type":"4"}},{"id":1246325,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":65667,"kind":"person","name":"Morgen Eric","position":1,"cik":"0002036289","reported_name":"Morgen Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-25T21:28:11.000Z","date":"2025-02-18","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents an employee stock option directly held by the reporting person's spouse."}],"balance_after":25000,"derivative":{"exercise_price":4.38,"expiration_date":"2035-02-17","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001415889-25-005496","document":"form4a-02252025_090206.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000141588925005496/form4a-02252025_090206.xml","form_type":"4/A","original_submission_date":"2025-02-20"}},{"id":1255825,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":53847,"kind":"person","name":"RUBIN PAUL D","position":1,"cik":"0001210905","reported_name":"RUBIN PAUL D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-20T21:22:32.000Z","date":"2025-02-18","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":200000,"derivative":{"exercise_price":4.38,"expiration_date":"2035-02-17","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001415889-25-004867","document":"form4-02202025_090226.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000141588925004867/form4-02202025_090226.xml","form_type":"4"}},{"id":1255826,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":65667,"kind":"person","name":"Morgen Eric","position":1,"cik":"0002036289","reported_name":"Morgen Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-20T21:21:02.000Z","date":"2025-02-18","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":200000,"derivative":{"exercise_price":4.38,"expiration_date":"2035-02-17","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001415889-25-004864","document":"form4-02202025_090258.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000141588925004864/form4-02202025_090258.xml","form_type":"4"}},{"id":1256857,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-20T21:19:02.000Z","date":"2025-02-18","kind":"grant","planned":false,"acquired":true,"shares":170000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":170000,"derivative":{"exercise_price":4.38,"expiration_date":"2035-02-17","underlying":"Common Stock","underlying_shares":170000},"source":{"system":"sec-edgar","filing":"0001415889-25-004859","document":"form4-02202025_090258.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000141588925004859/form4-02202025_090258.xml","form_type":"4"}},{"id":1255821,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":34002,"kind":"person","name":"Barton Shane","position":1,"cik":"0001836297","reported_name":"Barton Shane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-20T21:15:32.000Z","date":"2025-02-18","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":90000,"derivative":{"exercise_price":4.38,"expiration_date":"2035-02-17","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001415889-25-004854","document":"form4-02202025_090229.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000141588925004854/form4-02202025_090229.xml","form_type":"4"}},{"id":1256320,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":65690,"kind":"person","name":"Fortney Kristen","position":1,"cik":"0002032751","reported_name":"Fortney Kristen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-20T16:17:02.000Z","date":"2025-02-18","kind":"grant","planned":false,"acquired":true,"shares":530000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":530000,"derivative":{"exercise_price":4.38,"expiration_date":"2035-02-17","underlying":"Common Stock","underlying_shares":530000},"source":{"system":"sec-edgar","filing":"0001415889-25-004857","document":"form4-02202025_090259.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2032751/000141588925004857/form4-02202025_090259.xml","form_type":"4"}},{"id":1324151,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":34002,"kind":"person","name":"Barton Shane","position":1,"cik":"0001836297","reported_name":"Barton Shane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-20T21:04:55.000Z","date":"2024-12-18","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest as to 1/48th of the total award monthly, with the first tranche vesting on October 26, 2024, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":40000,"derivative":{"exercise_price":4.3,"expiration_date":"2034-12-17","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001415889-24-029962","document":"form4-12202024_091252.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000141588924029962/form4-12202024_091252.xml","form_type":"4"}},{"id":1392100,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":38749,"kind":"person","name":"Pande Vijay Satyanand","position":1,"cik":"0001840663","reported_name":"Pande Vijay Satyanand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-03T23:19:49.000Z","date":"2024-10-03","kind":"purchase","planned":false,"acquired":true,"shares":25306,"price":19.9,"value":503589.4,"ownership":{"direct":false,"nature":"Andreessen Horowitz LSV Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $19.78 to $19.95 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held of record by Andreessen Horowitz LSV Fund III, L.P. (\"AH LSV Fund III\"), for itself and as nominee for Andreessen Horowitz LSV Fund III-B, L.P. (\"AH LSV Fund III-B\") and AH 2022 Annual Fund, L.P. (\"AH 2022 Annual\" and together with AH LSV Fund III and AH LSV Fund III-B, the \"AH LSV Fund III Entities\"). AH Equity Partners LSV III, L.L.C. (\"AH EP LSV III\"), the general partner of AH LSV Fund III and AH LSV Fund III-B, may be deemed to have sole voting and dispositive power over the shares held by AH LSV Fund III and AH LSV Fund III-B. AH Equity Partners 2022 Annual Fund, L.L.C. (\"AH EP 2022 Annual\"), the general partner of AH 2022 Annual, may be deemed to have sole voting and dispositive power over the shares held by AH 2022 Annual."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reporting person serves as one of the members of the AH GP Entities, but he disclaims the existence of a \"group\" (as that term is used in Section 13(d) of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")), and disclaims beneficial ownership of the securities directly held by the AH Fund Entities, and this report shall not be deemed an admission that he is the beneficial owner of the securities reported herein for purposes of Section 16 of the Exchange Act, or for any other purpose, except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The managing members of each of: (i) AH EP Bio I; (ii) AH EP Bio III; (iii) AH EP Bio IV; (iv) AH EP LSV III; and (v) AH EP 2022 Annual (collectively, the \"AH GP Entities\") are Marc Andreessen and Ben Horowitz, and each of them may be deemed to share voting and investment discretion with respect to securities directly held by the AH Fund Entities."}],"balance_after":1119195,"source":{"system":"sec-edgar","filing":"0001415889-24-024688","document":"form4-10032024_111046.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000141588924024688/form4-10032024_111046.xml","form_type":"4"}},{"id":1392099,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":38749,"kind":"person","name":"Pande Vijay Satyanand","position":1,"cik":"0001840663","reported_name":"Pande Vijay Satyanand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-03T23:19:49.000Z","date":"2024-10-02","kind":"purchase","planned":false,"acquired":true,"shares":67096,"price":19.73,"value":1323804.08,"ownership":{"direct":false,"nature":"Andreessen Horowitz LSV Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $19.50 to $19.95 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held of record by Andreessen Horowitz LSV Fund III, L.P. (\"AH LSV Fund III\"), for itself and as nominee for Andreessen Horowitz LSV Fund III-B, L.P. (\"AH LSV Fund III-B\") and AH 2022 Annual Fund, L.P. (\"AH 2022 Annual\" and together with AH LSV Fund III and AH LSV Fund III-B, the \"AH LSV Fund III Entities\"). AH Equity Partners LSV III, L.L.C. (\"AH EP LSV III\"), the general partner of AH LSV Fund III and AH LSV Fund III-B, may be deemed to have sole voting and dispositive power over the shares held by AH LSV Fund III and AH LSV Fund III-B. AH Equity Partners 2022 Annual Fund, L.L.C. (\"AH EP 2022 Annual\"), the general partner of AH 2022 Annual, may be deemed to have sole voting and dispositive power over the shares held by AH 2022 Annual."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reporting person serves as one of the members of the AH GP Entities, but he disclaims the existence of a \"group\" (as that term is used in Section 13(d) of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")), and disclaims beneficial ownership of the securities directly held by the AH Fund Entities, and this report shall not be deemed an admission that he is the beneficial owner of the securities reported herein for purposes of Section 16 of the Exchange Act, or for any other purpose, except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The managing members of each of: (i) AH EP Bio I; (ii) AH EP Bio III; (iii) AH EP Bio IV; (iv) AH EP LSV III; and (v) AH EP 2022 Annual (collectively, the \"AH GP Entities\") are Marc Andreessen and Ben Horowitz, and each of them may be deemed to share voting and investment discretion with respect to securities directly held by the AH Fund Entities."}],"balance_after":1093889,"source":{"system":"sec-edgar","filing":"0001415889-24-024688","document":"form4-10032024_111046.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000141588924024688/form4-10032024_111046.xml","form_type":"4"}},{"id":1392098,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":38749,"kind":"person","name":"Pande Vijay Satyanand","position":1,"cik":"0001840663","reported_name":"Pande Vijay Satyanand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-03T23:19:49.000Z","date":"2024-10-01","kind":"purchase","planned":false,"acquired":true,"shares":126793,"price":19.73,"value":2501625.89,"ownership":{"direct":false,"nature":"Andreessen Horowitz LSV Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $19.49 to $20.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held of record by Andreessen Horowitz LSV Fund III, L.P. (\"AH LSV Fund III\"), for itself and as nominee for Andreessen Horowitz LSV Fund III-B, L.P. (\"AH LSV Fund III-B\") and AH 2022 Annual Fund, L.P. (\"AH 2022 Annual\" and together with AH LSV Fund III and AH LSV Fund III-B, the \"AH LSV Fund III Entities\"). AH Equity Partners LSV III, L.L.C. (\"AH EP LSV III\"), the general partner of AH LSV Fund III and AH LSV Fund III-B, may be deemed to have sole voting and dispositive power over the shares held by AH LSV Fund III and AH LSV Fund III-B. AH Equity Partners 2022 Annual Fund, L.L.C. (\"AH EP 2022 Annual\"), the general partner of AH 2022 Annual, may be deemed to have sole voting and dispositive power over the shares held by AH 2022 Annual."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reporting person serves as one of the members of the AH GP Entities, but he disclaims the existence of a \"group\" (as that term is used in Section 13(d) of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")), and disclaims beneficial ownership of the securities directly held by the AH Fund Entities, and this report shall not be deemed an admission that he is the beneficial owner of the securities reported herein for purposes of Section 16 of the Exchange Act, or for any other purpose, except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The managing members of each of: (i) AH EP Bio I; (ii) AH EP Bio III; (iii) AH EP Bio IV; (iv) AH EP LSV III; and (v) AH EP 2022 Annual (collectively, the \"AH GP Entities\") are Marc Andreessen and Ben Horowitz, and each of them may be deemed to share voting and investment discretion with respect to securities directly held by the AH Fund Entities."}],"balance_after":1026793,"source":{"system":"sec-edgar","filing":"0001415889-24-024688","document":"form4-10032024_111046.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000141588924024688/form4-10032024_111046.xml","form_type":"4"}},{"id":1396780,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25048,"kind":"organization","name":"Cormorant Private Healthcare Fund V LP","position":2,"cik":"0001969296","reported_name":"Cormorant Private Healthcare Fund V LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25044,"kind":"person","name":"Chen Bihua","position":3,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":74741,"kind":"organization","name":"Cormorant Private Healthcare Fund IV LP","position":4,"cik":"0001871297","reported_name":"Cormorant Private Healthcare Fund IV LP","relationship":{"other":true,"other_text":"Former 10% Owner"}}],"security":"Series D Redeemable Convertible Preferred Stock","published_at":"2024-10-01T20:01:04.000Z","date":"2024-09-27","kind":"exercise","planned":false,"acquired":false,"shares":5263772,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Series D Redeemable Convertible Preferred Stock (\"Series D Preferred Stock\") automatically converted into 0.224084614 shares of Common Stock of the Issuer (\"Common Stock\") upon the closing of the Issuer's initial public offering of Common Stock.  The Series D Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Series D Redeemable Convertible Preferred Stock (\"Series D Preferred Stock\") automatically converted into 0.224084614 shares of Common Stock of the Issuer (\"Common Stock\") upon the closing of the Issuer's initial public offering of Common Stock.  The Series D Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Series D Redeemable Convertible Preferred Stock (\"Series D Preferred Stock\") automatically converted into 0.224084614 shares of Common Stock of the Issuer (\"Common Stock\") upon the closing of the Issuer's initial public offering of Common Stock.  The Series D Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Series D Redeemable Convertible Preferred Stock (\"Series D Preferred Stock\") automatically converted into 0.224084614 shares of Common Stock of the Issuer (\"Common Stock\") upon the closing of the Issuer's initial public offering of Common Stock.  The Series D Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Each share of the Series D Redeemable Convertible Preferred Stock (\"Series D Preferred Stock\") automatically converted into 0.224084614 shares of Common Stock of the Issuer (\"Common Stock\") upon the closing of the Issuer's initial public offering of Common Stock.  The Series D Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents (i) 173,704 shares of Series D Preferred Stock beneficially owned by the Master Fund (defined below), which converted into 38,924 shares of Common Stock, (ii) 2,769,271 shares of Series D Preferred Stock beneficially owned by Fund IV (defined below), which converted into 620,551 shares of Common Stock, and (iii) 2,320,797 shares of Series D Preferred Stock beneficially owned by Fund V (defined below), which converted into 520,054 shares of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"), Cormorant Private Healthcare Fund IV, LP (\"Fund IV\") and Cormorant Private Healthcare Fund V, LP (\"Fund V\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\"), Cormorant Private Healthcare GP IV, LLC (\"GP IV\") and Cormorant Private Healthcare GP V, LLC (\"GP V\") serve as General Partner of the Master Fund, Fund IV and Fund V, respectively. Bihua Chen serves as manager of Cormorant, GP LLC, GP IV  and GP V. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1179529},"source":{"system":"sec-edgar","filing":"0000929638-24-003363","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000092963824003363/form4.xml","form_type":"4"}},{"id":1396779,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25048,"kind":"organization","name":"Cormorant Private Healthcare Fund V LP","position":2,"cik":"0001969296","reported_name":"Cormorant Private Healthcare Fund V LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25044,"kind":"person","name":"Chen Bihua","position":3,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":74741,"kind":"organization","name":"Cormorant Private Healthcare Fund IV LP","position":4,"cik":"0001871297","reported_name":"Cormorant Private Healthcare Fund IV LP","relationship":{"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2024-10-01T20:01:04.000Z","date":"2024-09-27","kind":"purchase","planned":false,"acquired":true,"shares":450000,"price":18,"value":8100000.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"), Cormorant Private Healthcare Fund IV, LP (\"Fund IV\") and Cormorant Private Healthcare Fund V, LP (\"Fund V\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\"), Cormorant Private Healthcare GP IV, LLC (\"GP IV\") and Cormorant Private Healthcare GP V, LLC (\"GP V\") serve as General Partner of the Master Fund, Fund IV and Fund V, respectively. Bihua Chen serves as manager of Cormorant, GP LLC, GP IV  and GP V. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares of Common Stock purchased for the account of the Master Fund."}],"balance_after":1629529,"source":{"system":"sec-edgar","filing":"0000929638-24-003363","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000092963824003363/form4.xml","form_type":"4"}},{"id":1396778,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25048,"kind":"organization","name":"Cormorant Private Healthcare Fund V LP","position":2,"cik":"0001969296","reported_name":"Cormorant Private Healthcare Fund V LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25044,"kind":"person","name":"Chen Bihua","position":3,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":74741,"kind":"organization","name":"Cormorant Private Healthcare Fund IV LP","position":4,"cik":"0001871297","reported_name":"Cormorant Private Healthcare Fund IV LP","relationship":{"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2024-10-01T20:01:04.000Z","date":"2024-09-27","kind":"exercise","planned":false,"acquired":true,"shares":1179529,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Series D Redeemable Convertible Preferred Stock (\"Series D Preferred Stock\") automatically converted into 0.224084614 shares of Common Stock of the Issuer (\"Common Stock\") upon the closing of the Issuer's initial public offering of Common Stock.  The Series D Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Each share of the Series D Redeemable Convertible Preferred Stock (\"Series D Preferred Stock\") automatically converted into 0.224084614 shares of Common Stock of the Issuer (\"Common Stock\") upon the closing of the Issuer's initial public offering of Common Stock.  The Series D Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents (i) 173,704 shares of Series D Preferred Stock beneficially owned by the Master Fund (defined below), which converted into 38,924 shares of Common Stock, (ii) 2,769,271 shares of Series D Preferred Stock beneficially owned by Fund IV (defined below), which converted into 620,551 shares of Common Stock, and (iii) 2,320,797 shares of Series D Preferred Stock beneficially owned by Fund V (defined below), which converted into 520,054 shares of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"), Cormorant Private Healthcare Fund IV, LP (\"Fund IV\") and Cormorant Private Healthcare Fund V, LP (\"Fund V\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\"), Cormorant Private Healthcare GP IV, LLC (\"GP IV\") and Cormorant Private Healthcare GP V, LLC (\"GP V\") serve as General Partner of the Master Fund, Fund IV and Fund V, respectively. Bihua Chen serves as manager of Cormorant, GP LLC, GP IV  and GP V. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":1179529,"source":{"system":"sec-edgar","filing":"0000929638-24-003363","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000092963824003363/form4.xml","form_type":"4"}},{"id":1398493,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":38749,"kind":"person","name":"Pande Vijay Satyanand","position":1,"cik":"0001840663","reported_name":"Pande Vijay Satyanand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series D Preferred Stock","published_at":"2024-09-27T20:28:00.000Z","date":"2024-09-27","kind":"exercise","planned":false,"acquired":false,"shares":2924318,"ownership":{"direct":false,"nature":"AH Bio Fund IV, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series D Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614.  The securities have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series D Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614.  The securities have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series D Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614.  The securities have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series D Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614.  The securities have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The managing members of each of:  (i) AH EP Bio I; (ii) AH EP Bio III;  (iii) AH EP Bio IV; (iv) AH EP LSV III; and (v) AH EP 2022 Annual (collectively, the \"AH GP Entities\") are Marc Andreessen and Ben Horowitz, and each of them may be deemed to share voting and investment discretion with respect to securities directly held by the AH Fund Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reporting person serves as one of the members of the AH GP Entities, but he disclaims the existence of a \"group\" (as that term is used in Section 13(d) of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")), and disclaims beneficial ownership of the securities directly held by the AH Fund Entities, and this report shall not be deemed an admission that he is the beneficial owner of the securities reported herein for purposes of Section 16 of the Exchange Act, or for any other purpose, except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The securities reported in this row are held by AH Bio Fund IV, L.P., for itself and as nominee for:  (i) AH Bio Fund IV-B, L.P.; (ii) AH 2022 Annual Fund, L.P.; (iii) AH 2022 Annual Fund-B, L.P.; (iv) AH 2022 Annual Fund-QC, L.P.; and (v) CLF Partners III, LP (collectively, the \"AH Bio Fund IV Entities\").  AH Equity Partners Bio IV, L.L.C. (\"AH EP Bio IV\") is the general partner of the AH Bio Fund IV Entities and may be deemed to exercise voting and investment discretion with respect to securities directly held by them."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":655294},"source":{"system":"sec-edgar","filing":"0001415889-24-024047","document":"form4-09272024_080956.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000141588924024047/form4-09272024_080956.xml","form_type":"4"}},{"id":1398492,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":38749,"kind":"person","name":"Pande Vijay Satyanand","position":1,"cik":"0001840663","reported_name":"Pande Vijay Satyanand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C Preferred Stock","published_at":"2024-09-27T20:28:00.000Z","date":"2024-09-27","kind":"exercise","planned":false,"acquired":false,"shares":846152,"ownership":{"direct":false,"nature":"AH Bio Fund III, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series C Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614.  The securities have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series C Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614.  The securities have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series C Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614.  The securities have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series C Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614.  The securities have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The managing members of each of:  (i) AH EP Bio I; (ii) AH EP Bio III;  (iii) AH EP Bio IV; (iv) AH EP LSV III; and (v) AH EP 2022 Annual (collectively, the \"AH GP Entities\") are Marc Andreessen and Ben Horowitz, and each of them may be deemed to share voting and investment discretion with respect to securities directly held by the AH Fund Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reporting person serves as one of the members of the AH GP Entities, but he disclaims the existence of a \"group\" (as that term is used in Section 13(d) of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")), and disclaims beneficial ownership of the securities directly held by the AH Fund Entities, and this report shall not be deemed an admission that he is the beneficial owner of the securities reported herein for purposes of Section 16 of the Exchange Act, or for any other purpose, except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The securities reported in this row are held by AH Bio Fund III, L.P., for itself and as nominee for AH Bio Fund III-B, L.P. and AH Bio Fund III-Q, L.P. (collectively, the \"AH Bio Fund III Entities\").  AH Equity Partners Bio III, L.L.C. (\"AH EP Bio III\") is the general partner of the AH Bio Fund III Entities and may be deemed to exercise voting and investment discretion with respect to securities directly held by them."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":189609},"source":{"system":"sec-edgar","filing":"0001415889-24-024047","document":"form4-09272024_080956.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000141588924024047/form4-09272024_080956.xml","form_type":"4"}},{"id":1398491,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":38749,"kind":"person","name":"Pande Vijay Satyanand","position":1,"cik":"0001840663","reported_name":"Pande Vijay Satyanand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2024-09-27T20:28:00.000Z","date":"2024-09-27","kind":"exercise","planned":false,"acquired":false,"shares":1843502,"ownership":{"direct":false,"nature":"AH Bio Fund I, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614.  The securities have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614.  The securities have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614.  The securities have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614.  The securities have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported in this row are held by AH Bio Fund I, L.P. for itself and as nominee for AH Bio Fund I-B, L.P. (collectively, the \"AH Bio Fund I Entities\").  AH Equity Partners Bio I, L.L.C. (\"AH EP Bio I\") is the general partner of the AH Bio Fund I Entities and may be deemed to exercise voting and investment discretion with respect to securities directly held by them."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The managing members of each of:  (i) AH EP Bio I; (ii) AH EP Bio III;  (iii) AH EP Bio IV; (iv) AH EP LSV III; and (v) AH EP 2022 Annual (collectively, the \"AH GP Entities\") are Marc Andreessen and Ben Horowitz, and each of them may be deemed to share voting and investment discretion with respect to securities directly held by the AH Fund Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reporting person serves as one of the members of the AH GP Entities, but he disclaims the existence of a \"group\" (as that term is used in Section 13(d) of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")), and disclaims beneficial ownership of the securities directly held by the AH Fund Entities, and this report shall not be deemed an admission that he is the beneficial owner of the securities reported herein for purposes of Section 16 of the Exchange Act, or for any other purpose, except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":413100},"source":{"system":"sec-edgar","filing":"0001415889-24-024047","document":"form4-09272024_080956.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000141588924024047/form4-09272024_080956.xml","form_type":"4"}},{"id":1398490,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":38749,"kind":"person","name":"Pande Vijay Satyanand","position":1,"cik":"0001840663","reported_name":"Pande Vijay Satyanand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-1 Preferred Stock","published_at":"2024-09-27T20:28:00.000Z","date":"2024-09-27","kind":"exercise","planned":false,"acquired":false,"shares":3819863,"ownership":{"direct":false,"nature":"AH Bio Fund I, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series A-1 Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614.  The securities have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series A-1 Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614.  The securities have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series A-1 Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614.  The securities have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series A-1 Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614.  The securities have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported in this row are held by AH Bio Fund I, L.P. for itself and as nominee for AH Bio Fund I-B, L.P. (collectively, the \"AH Bio Fund I Entities\").  AH Equity Partners Bio I, L.L.C. (\"AH EP Bio I\") is the general partner of the AH Bio Fund I Entities and may be deemed to exercise voting and investment discretion with respect to securities directly held by them."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The managing members of each of:  (i) AH EP Bio I; (ii) AH EP Bio III;  (iii) AH EP Bio IV; (iv) AH EP LSV III; and (v) AH EP 2022 Annual (collectively, the \"AH GP Entities\") are Marc Andreessen and Ben Horowitz, and each of them may be deemed to share voting and investment discretion with respect to securities directly held by the AH Fund Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reporting person serves as one of the members of the AH GP Entities, but he disclaims the existence of a \"group\" (as that term is used in Section 13(d) of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")), and disclaims beneficial ownership of the securities directly held by the AH Fund Entities, and this report shall not be deemed an admission that he is the beneficial owner of the securities reported herein for purposes of Section 16 of the Exchange Act, or for any other purpose, except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":855972},"source":{"system":"sec-edgar","filing":"0001415889-24-024047","document":"form4-09272024_080956.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000141588924024047/form4-09272024_080956.xml","form_type":"4"}},{"id":1398489,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":38749,"kind":"person","name":"Pande Vijay Satyanand","position":1,"cik":"0001840663","reported_name":"Pande Vijay Satyanand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-27T20:28:00.000Z","date":"2024-09-27","kind":"purchase","planned":false,"acquired":true,"shares":900000,"price":18,"value":16200000.0,"ownership":{"direct":false,"nature":"Andreessen Horowitz LSV Fund III, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The managing members of each of:  (i) AH EP Bio I; (ii) AH EP Bio III;  (iii) AH EP Bio IV; (iv) AH EP LSV III; and (v) AH EP 2022 Annual (collectively, the \"AH GP Entities\") are Marc Andreessen and Ben Horowitz, and each of them may be deemed to share voting and investment discretion with respect to securities directly held by the AH Fund Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reporting person serves as one of the members of the AH GP Entities, but he disclaims the existence of a \"group\" (as that term is used in Section 13(d) of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")), and disclaims beneficial ownership of the securities directly held by the AH Fund Entities, and this report shall not be deemed an admission that he is the beneficial owner of the securities reported herein for purposes of Section 16 of the Exchange Act, or for any other purpose, except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The securities reported in this row are held by Andreessen Horowitz LSV Fund III, L.P. (\"AH LSV Fund III\"), for itself and as nominee for Andreessen Horowitz LSV Fund III-B, L.P. (\"AH LSV Fund III-B\") and AH 2022 Annual Fund, L.P. (\"AH 2022 Annual\" and, collectively with AH LSV Fund III and AH LSV Fund III-B, the \"AH LSV Fund III Entities\"). AH Equity Partners LSV III, L.L.C. (\"AH EP LSV III\") is the general partner of AH LSV Fund III and AH LSV Fund III-B and may be deemed to exercise voting and investment discretion with respect to securities directly held by them.  AH Equity Partners 2022 Annual Fund, L.L.C. (\"AH EP 2022 Annual\") is the general partner of AH 2022 Annual and may be deemed to exercise voting and investment discretion with respect to securities directly held by it.  The AH Bio Fund I Entities, the AH Bio Fund III Entities, the AH Bio Fund IV Entities and the AH LSV Fund III Entities are collectively referred to herein as the \"AH Fund Entities.\""}],"balance_after":900000,"source":{"system":"sec-edgar","filing":"0001415889-24-024047","document":"form4-09272024_080956.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000141588924024047/form4-09272024_080956.xml","form_type":"4"}},{"id":1398488,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":38749,"kind":"person","name":"Pande Vijay Satyanand","position":1,"cik":"0001840663","reported_name":"Pande Vijay Satyanand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-27T20:28:00.000Z","date":"2024-09-27","kind":"exercise","planned":false,"acquired":true,"shares":655294,"ownership":{"direct":false,"nature":"AH Bio Fund IV, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series D Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614.  The securities have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The managing members of each of:  (i) AH EP Bio I; (ii) AH EP Bio III;  (iii) AH EP Bio IV; (iv) AH EP LSV III; and (v) AH EP 2022 Annual (collectively, the \"AH GP Entities\") are Marc Andreessen and Ben Horowitz, and each of them may be deemed to share voting and investment discretion with respect to securities directly held by the AH Fund Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reporting person serves as one of the members of the AH GP Entities, but he disclaims the existence of a \"group\" (as that term is used in Section 13(d) of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")), and disclaims beneficial ownership of the securities directly held by the AH Fund Entities, and this report shall not be deemed an admission that he is the beneficial owner of the securities reported herein for purposes of Section 16 of the Exchange Act, or for any other purpose, except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The securities reported in this row are held by AH Bio Fund IV, L.P., for itself and as nominee for:  (i) AH Bio Fund IV-B, L.P.; (ii) AH 2022 Annual Fund, L.P.; (iii) AH 2022 Annual Fund-B, L.P.; (iv) AH 2022 Annual Fund-QC, L.P.; and (v) CLF Partners III, LP (collectively, the \"AH Bio Fund IV Entities\").  AH Equity Partners Bio IV, L.L.C. (\"AH EP Bio IV\") is the general partner of the AH Bio Fund IV Entities and may be deemed to exercise voting and investment discretion with respect to securities directly held by them."}],"balance_after":655294,"source":{"system":"sec-edgar","filing":"0001415889-24-024047","document":"form4-09272024_080956.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000141588924024047/form4-09272024_080956.xml","form_type":"4"}},{"id":1398487,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":38749,"kind":"person","name":"Pande Vijay Satyanand","position":1,"cik":"0001840663","reported_name":"Pande Vijay Satyanand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-27T20:28:00.000Z","date":"2024-09-27","kind":"exercise","planned":false,"acquired":true,"shares":189609,"ownership":{"direct":false,"nature":"AH Bio Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series C Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614.  The securities have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The managing members of each of:  (i) AH EP Bio I; (ii) AH EP Bio III;  (iii) AH EP Bio IV; (iv) AH EP LSV III; and (v) AH EP 2022 Annual (collectively, the \"AH GP Entities\") are Marc Andreessen and Ben Horowitz, and each of them may be deemed to share voting and investment discretion with respect to securities directly held by the AH Fund Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reporting person serves as one of the members of the AH GP Entities, but he disclaims the existence of a \"group\" (as that term is used in Section 13(d) of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")), and disclaims beneficial ownership of the securities directly held by the AH Fund Entities, and this report shall not be deemed an admission that he is the beneficial owner of the securities reported herein for purposes of Section 16 of the Exchange Act, or for any other purpose, except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The securities reported in this row are held by AH Bio Fund III, L.P., for itself and as nominee for AH Bio Fund III-B, L.P. and AH Bio Fund III-Q, L.P. (collectively, the \"AH Bio Fund III Entities\").  AH Equity Partners Bio III, L.L.C. (\"AH EP Bio III\") is the general partner of the AH Bio Fund III Entities and may be deemed to exercise voting and investment discretion with respect to securities directly held by them."}],"balance_after":189609,"source":{"system":"sec-edgar","filing":"0001415889-24-024047","document":"form4-09272024_080956.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000141588924024047/form4-09272024_080956.xml","form_type":"4"}},{"id":1398486,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":38749,"kind":"person","name":"Pande Vijay Satyanand","position":1,"cik":"0001840663","reported_name":"Pande Vijay Satyanand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-27T20:28:00.000Z","date":"2024-09-27","kind":"exercise","planned":false,"acquired":true,"shares":413100,"ownership":{"direct":false,"nature":"AH Bio Fund I, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614.  The securities have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported in this row are held by AH Bio Fund I, L.P. for itself and as nominee for AH Bio Fund I-B, L.P. (collectively, the \"AH Bio Fund I Entities\").  AH Equity Partners Bio I, L.L.C. (\"AH EP Bio I\") is the general partner of the AH Bio Fund I Entities and may be deemed to exercise voting and investment discretion with respect to securities directly held by them."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The managing members of each of:  (i) AH EP Bio I; (ii) AH EP Bio III;  (iii) AH EP Bio IV; (iv) AH EP LSV III; and (v) AH EP 2022 Annual (collectively, the \"AH GP Entities\") are Marc Andreessen and Ben Horowitz, and each of them may be deemed to share voting and investment discretion with respect to securities directly held by the AH Fund Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reporting person serves as one of the members of the AH GP Entities, but he disclaims the existence of a \"group\" (as that term is used in Section 13(d) of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")), and disclaims beneficial ownership of the securities directly held by the AH Fund Entities, and this report shall not be deemed an admission that he is the beneficial owner of the securities reported herein for purposes of Section 16 of the Exchange Act, or for any other purpose, except to the extent of his pecuniary interest therein."}],"balance_after":1269072,"source":{"system":"sec-edgar","filing":"0001415889-24-024047","document":"form4-09272024_080956.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000141588924024047/form4-09272024_080956.xml","form_type":"4"}}],"next_cursor":"2024-09-27T20:28:00.000000Z,1398486"}